1. ScholarBank@NUS

Seng Gee Lim

rp00481

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Seng Gee Lim
Variants
Lee Lim, S.G.
Lim, S.G.
Seng, Foreword Gee Lim
Seng, G.L.
Lim Seng Gee
Lim, Seng Gee
Lim, S.-G.
 
Main Affiliation
 
Faculty
 
Email
mdclimsg@nus.edu.sg
 

Publications

Refined By:
Date Issued:  [2000 TO 3000]

Results 1-20 of 143 (Search time: 0.007 seconds).

Issue DateTitleAuthor(s)
12006A double-blind placebo-controlled study of emtricitabine in chronic hepatitis BLim, S.G. ; Ng, T.M.; Guan, R.; Kung, N.; Krastev, Z.; Volfova, M.; Husa, P.; Lee, S.S.; Chan, S.; Shiffman, M.L.; Washington, M.K.; Rigney, A.; Anderson, J.; Mondou, E.; Snow, A.; Sorbel, J.; Rousseau, F.
22010A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis BTan, A.T.; Koh, S.; Goh, W.; Gehring, A.J.; Bertoletti, A. ; Lim, S.G. ; Zhe, H.Y.
3Jun-2008A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)Lee, Y.-M. ; Sutedja, D.S.; Wai, C.-T. ; Dan, Y.-Y. ; Aung, M.-O. ; Zhou, L. ; Cheng, C.-L.; Wee, A.; Lim, S.-G. 
42006A randomized, placebo-controlled trial of thymosin-α1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis BLim, S.G. ; Wai, C.-T. ; Lee, Y.M. ; Dan, Y.Y.; Sutedja, D.S.; Wee, A. ; Suresh, S.; Wu, Y.J.; Machin, D.; Lim, C.C.; Fock, K.M.; Koay, E.; Bowden, S.; Locarnini, S.; Ishaque, S.M.
52006A randomized, placebo-controlled trial of thymosin-α1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis BLim, S.G. ; Wai, C.-T. ; Lee, Y.M. ; Dan, Y.Y.; Sutedja, D.S.; Wee, A. ; Suresh, S.; Wu, Y.J.; Machin, D.; Lim, C.C.; Fock, K.M.; Koay, E. ; Bowden, S.; Locarnini, S.; Ishaque, S.M.
61-Oct-2017Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitionsRajoo, AS; Lim, SG ; Phyo, WW ; Tun, T; Dan, YY ; Lee, YM ; Low, HC ; Lim, K; Tan, PS; Lee, GH 
72004Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplantWai, C.-T.; Prabhakaran, K. ; Wee, A. ; Lee, Y.-M.; Dan, Y.-Y.; Sutedja, D.S.; Mak, K.; Isaac, J. ; Lee, K.-H. ; Lee, H.-L.; Da, Costa M. ; Lim, S.-G. 
82003Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BHadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.-T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G. ; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.
92003Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BMarcellin, P.; Chang, T.-T.; Lim, S.G. ; Tong, M.J.; Sievert, W.; Shiffman, M.L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L.
10Aug-2007Age in Guiding Strategy in Hepatitis A VaccinationWai, C.-T. ; Mak, B.; Aung, M.O. ; Lim, S.-G. 
112003An anti-HIV-1 gp120 antibody expressed as an endocytotic transmembrane protein mediates internalization of HIV-1Tan, Y.-J.; Lim, S.-P.; Ting, A.E.; Goh, P.-Y.; Tan, Y.H.; Lim, S.G. ; Hong, W.
12Apr-2012APASL consensus statements and management algorithms for hepatitis C virus infectionOmata, M.; Kanda, T.; Yu, M.-L.; Yokosuka, O.; Lim, S.-G. ; Jafri, W.; Tateishi, R.; Hamid, S.S.; Chuang, W.-L.; Chutaputti, A.; Wei, L.; Sollano, J.; Sarin, S.K.; Kao, J.-H.; McCaughan, G.W.
132007Applicability of cost-effectiveness analysis to management of chronic hepatitis BDan, Y.Y.; Lim, S.G. 
142006Are in vitro hepatitis B core promoter mutations important for clinical alterations in viral load?Cheng, Y. ; Seet, B.L.; Ong, C.S.L.; Wasser, S. ; Lim, S.G. ; Tan, T.M.C. ; Peter, F.J. 
152010Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaOmata, M.; Tateishi, R.; Yoshida, H.; Shiina, S.; Lesmana, L.A.; Budihusodo, U.; Lesmana, C.R.; Chen, P.-J.; Lin, S.-M.; Liaw, Y.F.; Kudo, M.; Lee, J.M.; Choi, B.I.; Poon, R.T.P.; Cheng, A.L.; Jia, J.-D.; Obi, S.; Han, K.H.; Jafri, W.; Chow, P.; Lim, S.G. ; Chawla, Y.K.; Gani, R.A.; Putranto, T.A.; Sarin, S.K.
16Jul-2009Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BZeuzem, S.; Gane, E.; Liaw, Y.-F.; Lim, S.G. ; DiBisceglie, A.; Buti, M.; Chutaputti, A.; Rasenack, J.; Hou, J.; O'Brien, C.; Nguyen, T.T.; Jia, J.; Poynard, T.; Belanger, B.; Bao, W.; Naoumov, N.V.
171-Dec-2021Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatmentNarayanan, S; Au, VB; Khakpoor, A ; Yan, C ; Ahl, PJ; Kaliaperumal, N; Lee, B; Xiang, WW; Wang, J ; Lee, C; Tay, A ; Lim, SG ; Connolly, JE 
182005Bilirubin appears to be the only independent variable affecting mortality on liver transplant waiting list if waiting time exceeds 1 yearLee, Y.-M. ; Wai, C.-T. ; Da, Costa M. ; Lee, K.-H. ; Sutedja, D.; Tan, K.-C.; Isaac, J. ; Lim, S.-G. 
192010C/EBPα Is Up-Regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and ProliferationLu, G. ; Leung, C.H. ; Tan, C.M.-Y.; Low, S.Y.; Hooi, S.C. ; Yan, B.; Salto-Tellez, M. ; Aung, M.O.; Lim, S.G. 
202003CD81 engineered with endocytotic signals mediates HCV cell entry: Implications for receptor usage by HCV in vivoTan, Y.-J.; Lim, S.-P.; Goh, P.-Y.; Lim, S.G. ; Tan, Y.H.; Hong, W. ; Ng, P.